Dagmar Schlenzig

Dr. Dagmar Schlenzig is a Lecturer in the Department of Applied Biosciences and Process Engineering at Anhalt University of Applied Sciences. Her academic career focuses on biochemistry and molecular biology with particular expertise in metalloproteases, especially the meprin family of astacin proteinases.

Dr. Schlenzig's research interests span several interconnected areas in biochemistry and neurodegenerative disease research. Her work primarily investigates the structure, function, and inhibition of meprin α and β proteases, with significant contributions to understanding their role in Alzheimer's disease pathology. She has developed various inhibitor classes including pyrazole-based compounds, heteroaromatic molecules, and tertiary-amine derivatives through structure-guided design approaches. A major focus of her recent work examines how meprin β's dipeptidyl-peptidase activity contributes to the formation of neurotoxic pyroglutamate-modified amyloid peptides in Alzheimer's disease.

Analysis of Dr. Schlenzig's publication record from 2018-2023 reveals a strong emphasis on enzyme kinetics, structural biology, and medicinal chemistry approaches to protease research. Her work demonstrates expertise in developing biochemical assays, determining protein structures, and designing targeted inhibitors with therapeutic potential, particularly for neurodegenerative conditions.

Dr. Schlenzig maintains active research collaborations as evidenced by her co-authorship on publications with researchers from various institutions. Her work with pharmaceutical companies like Vivoryon Therapeutics NV indicates potential translational applications of her basic research findings.

Her methodological expertise includes enzyme kinetics, protein purification, structural analysis techniques, molecular modeling, and chemical synthesis of inhibitors. This multidisciplinary approach enables comprehensive investigation of protease function and inhibition, bridging basic science with potential therapeutic applications.